Last reviewed · How we verify
M2ES 60mg
At a glance
| Generic name | M2ES 60mg |
|---|---|
| Also known as | M2ES 60mg IV D1,8,15,22, every 28days a cycle., M2ES 60mg intervention |
| Sponsor | Protgen Ltd |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Study of M2ES in Patients With Advanced Pancreatic Cancer After Gemcitabine Treatment Failure (PHASE1)
- Dose Escalation and PK Study of M2ES in Subjects With Advanced Solid Tumors (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- M2ES 60mg CI brief — competitive landscape report
- M2ES 60mg updates RSS · CI watch RSS
- Protgen Ltd portfolio CI